Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism

Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) announced its participation in the 14th International Congress of Inborn Errors of Metabolism from November 21-23, 2021. The company is presenting two digital posters: one on the long-term efficacy of migalastat in patients with amenable GLA variants and another on the incidence of Fabry disease in children. Both presentations highlight key findings relevant to the treatment of rare metabolic diseases. Interested parties can access these presentations through the Investors section of the Amicus website.

Positive

• Presentation of research findings at a prominent international congress enhances Amicus's credibility and visibility in the biotech field.
• Focus on migalastat shows ongoing commitment to advancing treatments for rare diseases, potentially attracting investor interest.

Negative

• None.

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021.

Digital Poster Presentations:

• Long-term multisystemic efficacy with migalastat in ERT-naïve and ERT-experienced patients with amenable GLA variants
  • Presenter: Drago Bratkovic, MD, PARC Research Clinic, Adelaide, Australia

• Incidence and prevalence of newborn, paediatric, and adolescent patients with Fabry disease: a targeted literature review
  • Presenter: Ian Keyzor, Amicus Therapeutics, Marlow, United Kingdom

The posters can be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com.

For more information on the International Congress of Inborn Errors of Metabolism 2021, please visit www.iciem2021.com.au.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.

CONTACT:

Investors:
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Diana Moore
Head of Global Corporate Affairs & Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G

FAQ

What are the key highlights of Amicus Therapeutics' presentations at ICIEM 2021?

Amicus Therapeutics presented two digital posters focusing on migalastat's long-term efficacy in patients and the prevalence of Fabry disease among children at ICIEM 2021.

When is the International Congress of Inborn Errors of Metabolism taking place?

The congress is being held virtually and in Sydney, Australia from November 21 to November 23, 2021.

How can I access Amicus Therapeutics' presentation materials?

The presentation materials can be accessed via the Investors section of Amicus Therapeutics' corporate website.